{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:18:50Z","timestamp":1790893130297,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clml.2015.08.086","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T10:49:21Z","timestamp":1441277361000},"page":"739-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Essential Thrombocythemia: The Dermatologic Point of View"],"prefix":"10.1016","volume":"15","author":[{"given":"Emanuele","family":"Cozzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Pierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.08.086_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.08.086_bib2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2012.08.011","article-title":"Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture","volume":"36","author":"Tefferi","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.08.086_bib3","series-title":"WHO Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues","first-page":"48","author":"Jaffe","year":"2008"},{"key":"10.1016\/j.clml.2015.08.086_bib4","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"48","article-title":"Essential thrombocythaemia","author":"Thiele","year":"2008"},{"key":"10.1016\/j.clml.2015.08.086_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","article-title":"Incidence, clinical features and outcome of essential thrombocythaemia in a well-defined geographical area","volume":"65","author":"Jensen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.08.086_bib6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"Gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.08.086_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.08.086_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/PPO.0b013e318159467b","article-title":"JAK2 mutations and clinical practice in myeloproliferative neoplasms","volume":"13","author":"Tefferi","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2015.08.086_bib9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2015.08.086_bib10","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2015.08.086_bib11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.086_bib12","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.08.086_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.08.086_bib14","first-page":"786","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br\u00a0J\u00a0Haematol"},{"key":"10.1016\/j.clml.2015.08.086_bib15","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.08.086_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2015.08.086_bib17","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.086_bib18","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.086_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0190-9622(91)70010-Y","article-title":"Cutaneous manifestations in patients with essential thrombocythemia","volume":"24","author":"Itin","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7326\/0003-4819-102-4-466","article-title":"Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia","volume":"102","author":"Michiels","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2015.08.086_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.08.086_bib22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1365-2133.2006.07430.x","article-title":"Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients","volume":"155","author":"Weisshaar","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib23","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/1097-0142(19880615)61:12<2487::AID-CNCR2820611217>3.0.CO;2-T","article-title":"Essential thrombocythemia: clinical characteristics and course of 61 cases","volume":"61","author":"Hehlmann","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.08.086_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.08.086_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.08.086_bib26","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.086_bib27","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.086_bib28","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1182\/blood-2008-09-179416","article-title":"Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders","volume":"113","author":"Ishii","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.086_bib29","first-page":"1","article-title":"Management and treatment of pruritus","volume":"12","author":"Lovell","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.clml.2015.08.086_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(08)80005-9","article-title":"Erythromelalgia and thrombocythemia: a causal relation","volume":"22","author":"Michiels","year":"1990","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-2007-996121","article-title":"Erythromelalgia and vascular complications in polycythemia vera","volume":"23","author":"Michiels","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2015.08.086_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11739-009-0319-3","article-title":"Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia","volume":"5","author":"Vannucchi","year":"2010","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clml.2015.08.086_bib33","first-page":"5","article-title":"Acrocyanosis: changing concepts and nosological limitations","volume":"26","author":"Planchon","year":"2001","journal-title":"J\u00a0Mal Vasc"},{"key":"10.1016\/j.clml.2015.08.086_bib34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archderm.1963.01590150018003","article-title":"Idiopathic thrombocythemia","volume":"87","author":"Champion","year":"1963","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaad.2004.11.051","article-title":"Livedo reticularis: an update","volume":"52","author":"Gibbs","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud's phenomenon","volume":"44","author":"Herrick","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clml.2015.08.086_bib37","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhsa.2007.05.010","article-title":"Digital ischemia due to essential thrombocythemia: a case report","volume":"32","author":"Papadonikolakis","year":"2007","journal-title":"J\u00a0Hand Surg Am"},{"key":"10.1016\/j.clml.2015.08.086_bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2008.06.004","article-title":"Raynaud's phenomenon: pathogenesis and management","volume":"59","author":"Bakst","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.2830490107","article-title":"Essential thrombocythemia: a retrospective analysis of 39 cases","volume":"49","author":"Kwong","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.08.086_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","article-title":"Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin","volume":"97","author":"van Genderen","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.08.086_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2230.2001.00782.x","article-title":"Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia","volume":"26","author":"Vassallo","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia","volume":"353","author":"Barbui","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.08.086_bib43","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/10428190400029817","article-title":"A\u00a0critical review of anagrelide therapy in essential thrombocythemia and related disorders","volume":"46","author":"Dingli","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.08.086_bib44","doi-asserted-by":"crossref","unstructured":"Gugliotta L, Papayannidis C, Piccin A, et\u00a0al. Hydroxyurea treatment in 1075 patients with essential thrombocythemia and occurrence of extra-hematological adverse events: a preliminary report of the Registro Italiano Trombocitemia (RIT). Blood (ASH Annual Meeting Abstracts) 2010; 116:1973.","DOI":"10.1182\/blood.V116.21.1973.1973"},{"key":"10.1016\/j.clml.2015.08.086_bib45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/cncr.26194","article-title":"Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug","volume":"118","author":"Latagliata","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.08.086_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09537100400020179","article-title":"Toxicity and side effects of hydroxyurea used for primary thrombocythemia","volume":"16","author":"Randi","year":"2005","journal-title":"Platelets"},{"key":"10.1016\/j.clml.2015.08.086_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","article-title":"Hydroxyurea-induced leg ulceration in 14 patients","volume":"128","author":"Best","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2015.08.086_bib48","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/archderm.135.7.818","article-title":"Leg ulcers and hydroxyurea: forty-one cases","volume":"135","author":"Sirieix","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib49","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00000637-199711000-00017","article-title":"Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders: a case report and review of the literature","volume":"39","author":"Cox","year":"1997","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.clml.2015.08.086_bib50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1046\/j.1365-2133.1998.2576l.x","article-title":"Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostaglandin E1 and pentoxifylline","volume":"139","author":"Kido","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.12968\/jowc.2010.19.8.77715","article-title":"Hydroxyurea-induced foot ulcer in a case of essential thrombocythaemia","volume":"19","author":"Tsuchiya","year":"2010","journal-title":"J\u00a0Wound Care"},{"key":"10.1016\/j.clml.2015.08.086_bib52","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0001-7310(09)72554-2","article-title":"Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea","volume":"100","author":"Martorell-Calatayud","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clml.2015.08.086_bib53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A\u00a0unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.08.086_bib54","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood.V94.4.1479","article-title":"Successful healing of hydroxyurea related leg ulcers with topical granulocyte macrophage colony stimulating factor","volume":"94","author":"Stagno","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.086_bib55","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2000.03068.x","article-title":"A\u00a0case of bleeding jejunal ulcer due to vasculitis from hydroxyurea","volume":"95","author":"Khurshid","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clml.2015.08.086_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-230X-14-134","article-title":"Hydroxyurea and colonic ulcers: a case report","volume":"14","author":"Boonyawat","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.clml.2015.08.086_bib57","first-page":"149","article-title":"Management of aphthous ulcers","volume":"62","author":"McBride","year":"2000","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clml.2015.08.086_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0248-8663(00)87226-4","article-title":"Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation","volume":"21","author":"Salmon-Ehr","year":"2000","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.clml.2015.08.086_bib59","first-page":"163","article-title":"The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea","volume":"131","author":"Snyder","year":"1984","journal-title":"Mutat Res"},{"key":"10.1016\/j.clml.2015.08.086_bib60","first-page":"136","article-title":"Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion","volume":"1","author":"Brash","year":"1996","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.clml.2015.08.086_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1203475415583414","article-title":"Non-melanoma skin cancer in Canada chapter 3: management of actinic keratosis","volume":"19","author":"Poulin","year":"2015","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.clml.2015.08.086_bib63","doi-asserted-by":"crossref","unstructured":"Szeimies RM, Hauschild A, Ortland C, Moor AC, Stocker M, Surber C. Photodynamic therapy simplified non-prepared, moderate grade actinic keratosis lesions respond equally well to 5-ALA patch photodynamic therapy as mild lesions do [e-pub ahead of print]. Br J Dermatol http:\/\/dx.doi.org\/10.1111\/bjd.13889. Accessed May 4, 2015.","DOI":"10.1111\/bjd.13889"},{"key":"10.1016\/j.clml.2015.08.086_bib64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000366546","article-title":"Conventional treatment of actinic keratosis: an overview","volume":"46","author":"Peris","year":"2015","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib65","doi-asserted-by":"crossref","unstructured":"G\u00f3mez M, Guillem V, Pereira A, et\u00a0al. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera [e-pub ahead of print]. Eur J Haematol http:\/\/dx.doi.org\/10.1111\/ejh.12588. Accessed May 21, 2015.","DOI":"10.1111\/ejh.12588"},{"key":"10.1016\/j.clml.2015.08.086_bib66","first-page":"E20","article-title":"Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation","volume":"95","author":"Knackstedt","year":"2015","journal-title":"Cutis"},{"key":"10.1016\/j.clml.2015.08.086_bib67","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaad.2003.11.059","article-title":"Hydroxyurea-associated squamous dysplasia","volume":"51","author":"Sanchez-Palacios","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib68","first-page":"395","article-title":"Effects of hydroxyurea and radiation on hair matrix cells","volume":"6","author":"Malkinson","year":"1973","journal-title":"Cell Tissue Kinet"},{"key":"10.1016\/j.clml.2015.08.086_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14740338.3.6.579","article-title":"Mucocutaneous side effects of antineoplastic chemotherapy","volume":"3","author":"Guillot","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clml.2015.08.086_bib70","first-page":"543","article-title":"Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches","volume":"12","author":"Hesketh","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2015.08.086_bib71","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","article-title":"Alopecia areata: an evidence-based treatment update","volume":"15","author":"Hordinsky","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib72","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1067\/mjd.2002.120910","article-title":"Nail pigmentation caused by hydroxyurea: report of 9 cases","volume":"47","author":"Aste","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib73","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0190-9622(08)80119-3","article-title":"Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding","volume":"24","author":"Vomvouras","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib74","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/09546630600780494","article-title":"Secondary cutaneous effects of hydroxyurea: possible pathogenetic mechanisms","volume":"17","author":"Zaccaria","year":"2006","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.clml.2015.08.086_bib75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-4632.2011.05105.x","article-title":"Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?","volume":"51","author":"Nofal","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2133.1995.tb02677.x","article-title":"Hydroxyurea-induced dermatomyositis-like eruption","volume":"133","author":"Senet","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib77","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archdermatol.2010.11","article-title":"Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure","volume":"146","author":"Kalajian","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib78","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.08.086_bib79","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.086_bib80","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.086_bib81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamadermatol.2013.1989","article-title":"Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection","volume":"149","author":"Tsilika","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clml.2015.08.086_bib82","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.086_bib83","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-2007-959325","article-title":"Appearance of leg ulcers associated with intake of anagrelide","volume":"132","author":"Rappoport","year":"2007","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.clml.2015.08.086_bib84","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.4065\/73.11.1125","article-title":"Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia","volume":"73","author":"Ruiz-Arg\u00fcelles","year":"1998","journal-title":"Mayo Clin Proc"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:53Z","timestamp":1761870413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015012446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S2152265015012446"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.08.086","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Essential Thrombocythemia: The Dermatologic Point of View","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.08.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}